Literature DB >> 11533489

Duration of nuclear NF-kappaB action regulated by reversible acetylation.

W Fischle, E Verdin, W C Greene.   

Abstract

The nuclear expression and action of the nuclear factor kappa B (NF-kappaB) transcription factor requires signal-coupled phosphorylation and degradation of the IkappaB inhibitors, which normally bind and sequester this pleiotropically active factor in the cytoplasm. The subsequent molecular events that regulate the termination of nuclear NF-kappaB action remain poorly defined, although the activation of de novo IkappaBalpha gene expression by NF-kappaB likely plays a key role. Our studies now demonstrate that the RelA subunit of NF-kappaB is subject to inducible acetylation and that acetylated forms of RelA interact weakly, if at all, with IkappaBalpha. Acetylated RelA is subsequently deacetylated through a specific interaction with histone deacetylase 3 (HDAC3). This deacetylation reaction promotes effective binding to IkappaBalpha and leads in turn to IkappaBalpha-dependent nuclear export of the complex through a chromosomal region maintenance-1 (CRM-1)-dependent pathway. Deacetylation of RelA by HDAC3 thus acts as an intranuclear molecular switch that both controls the duration of the NF-kappaB transcriptional response and contributes to the replenishment of the depleted cytoplasmic pool of latent NF-kappaB-IkappaBalpha complexes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11533489     DOI: 10.1126/science.1062374

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  448 in total

1.  Mutations in the v-Rel transactivation domain indicate altered phosphorylation and identify a subset of NF-kappaB-regulated cell death inhibitors important for v-Rel transforming activity.

Authors:  Béatrice Rayet; Yongjun Fan; Céline Gélinas
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

Review 2.  Selectivity of the NF-{kappa}B response.

Authors:  Ranjan Sen; Stephen T Smale
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10-14       Impact factor: 10.005

Review 3.  The therapeutic potential of epigenetics in autoimmune diseases.

Authors:  Maria De Santis; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2012-02       Impact factor: 8.667

4.  LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.

Authors:  Roberto Rosato; Stefanie Hock; Paul Dent; Yun Dai; Steven Grant
Journal:  Leuk Res       Date:  2011-11-08       Impact factor: 3.156

5.  Epigenetic changes induced by curcumin and other natural compounds.

Authors:  Simone Reuter; Subash C Gupta; Byoungduck Park; Ajay Goel; Bharat B Aggarwal
Journal:  Genes Nutr       Date:  2011-04-24       Impact factor: 5.523

6.  The CRM1 nuclear export receptor controls pathological cardiac gene expression.

Authors:  Brooke C Harrison; Charles R Roberts; David B Hood; Meghan Sweeney; Jody M Gould; Erik W Bush; Timothy A McKinsey
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

7.  Oxidative stress and TNF-alpha induce histone acetylation and NF-kappaB/AP-1 activation in alveolar epithelial cells: potential mechanism in gene transcription in lung inflammation.

Authors:  Irfan Rahman; Peter S Gilmour; Luis Albert Jimenez; William MacNee
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

8.  L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors.

Authors:  Carla Nasca; Dionysios Xenos; Ylenia Barone; Alessandra Caruso; Sergio Scaccianoce; Francesco Matrisciano; Giuseppe Battaglia; Aleksander A Mathé; Anna Pittaluga; Luana Lionetto; Maurizio Simmaco; Ferdinando Nicoletti
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

Review 9.  Epigenomics and breast cancer.

Authors:  Pang-Kuo Lo; Saraswati Sukumar
Journal:  Pharmacogenomics       Date:  2008-12       Impact factor: 2.533

10.  Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF.

Authors:  Shih-Min Huang; D J McCance
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.